Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lifeline for severe bleeding disorder: drug access extended

NCT ID NCT06173024

AVAILABLE Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This program provides continued compassionate access to recombinant von Willebrand factor (rVWF) for children and adults with severe von Willebrand disease who completed a prior study and are benefiting from treatment. Participants must have no comparable alternative therapy available. The goal is to prevent bleeding complications while no other options exist.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
recombinant von Willebrand factor (rVWF, TAK-577)
What this could lead to
If successful, this program ensures continued bleeding control for people with severe von Willebrand disease who have no other treatment options.
What could go wrong
This is an access program, not a new trial, so it does not test effectiveness or safety. Only a small number of eligible patients from one prior study can participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE VON WILLEBRAND DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary von Willebrand disease von Willebrand disease (hereditary or acquired)

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VON WILLEBRAND DISEASE (VWD)

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.